TY - JOUR
T1 - Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection
AU - Achenbach, Chad J.
AU - Harrington, Robert D.
AU - Dhanireddy, Shireesha
AU - Crane, Heidi M.
AU - Casper, Corey
AU - Kitahata, Mari M.
N1 - Funding Information:
Financial support. This work was supported by the University of Washington AIDS and STD Research Training Grant (National Institutes of Health T32 AI07140-31). Potential conflicts of interests. All authors: No reported conflicts.
PY - 2012/2/1
Y1 - 2012/2/1
N2 - Background. The incidence of immune reconstitution inflammatory syndrome (IRIS) when antiretroviral therapy (ART) is initiated after an AIDS-defining opportunistic infection (OI) is uncertain and understudied for the most common OIs. Methods. We examined patients in the University of Washington Human Immunodeficiency Virus Cohort initiating potent ART subsequent to an AIDS-defining OI. IRIS was determined through retrospective medical record review and adjudication using a standardized data collection process and clinical case definition. We compared demographic and clinical characteristics, and immunologic changes in patients with and without IRIS. Results. Among 196 patients with 260 OIs, 21 (11%; 95% confidence interval, 7%-16%) developed paradoxical IRIS in the first year on ART. The 3 most common OIs among study patients were Pneumocystis pneumonia (PCP, 28%), Candida esophagitis (23%), and Kaposi sarcoma (KS, 16%). Cumulative 1-year incidence of IRIS was 29% (12/41) for KS, 16% (4/25) for tuberculosis, 14% (1/7) for Cryptococcus, 10% (1/10) for Mycobacterium avium complex, and 4% (3/72) for PCP. Morbidity and mortality were highest in those with visceral KS-IRIS compared with other types of IRIS (100% [6/6] vs 7% [1/15], P<.01). Patients with mucocutaneous KS and tuberculosis-IRIS experienced greater median increase in CD4 + cell count during the first 6 months of ART compared with those without IRIS (+158 vs +53cells/μL, P=.04, mucocutaneous KS; +261 vs +113, P=.04, tuberculosis). Conclusions. Cumulative incidence and features of IRIS varied depending on the OI. IRIS occurred in >10% of patients with KS, tuberculosis, or Cryptococcus. Visceral KS-IRIS led to considerable morbidity and mortality.
AB - Background. The incidence of immune reconstitution inflammatory syndrome (IRIS) when antiretroviral therapy (ART) is initiated after an AIDS-defining opportunistic infection (OI) is uncertain and understudied for the most common OIs. Methods. We examined patients in the University of Washington Human Immunodeficiency Virus Cohort initiating potent ART subsequent to an AIDS-defining OI. IRIS was determined through retrospective medical record review and adjudication using a standardized data collection process and clinical case definition. We compared demographic and clinical characteristics, and immunologic changes in patients with and without IRIS. Results. Among 196 patients with 260 OIs, 21 (11%; 95% confidence interval, 7%-16%) developed paradoxical IRIS in the first year on ART. The 3 most common OIs among study patients were Pneumocystis pneumonia (PCP, 28%), Candida esophagitis (23%), and Kaposi sarcoma (KS, 16%). Cumulative 1-year incidence of IRIS was 29% (12/41) for KS, 16% (4/25) for tuberculosis, 14% (1/7) for Cryptococcus, 10% (1/10) for Mycobacterium avium complex, and 4% (3/72) for PCP. Morbidity and mortality were highest in those with visceral KS-IRIS compared with other types of IRIS (100% [6/6] vs 7% [1/15], P<.01). Patients with mucocutaneous KS and tuberculosis-IRIS experienced greater median increase in CD4 + cell count during the first 6 months of ART compared with those without IRIS (+158 vs +53cells/μL, P=.04, mucocutaneous KS; +261 vs +113, P=.04, tuberculosis). Conclusions. Cumulative incidence and features of IRIS varied depending on the OI. IRIS occurred in >10% of patients with KS, tuberculosis, or Cryptococcus. Visceral KS-IRIS led to considerable morbidity and mortality.
UR - http://www.scopus.com/inward/record.url?scp=84855877378&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855877378&partnerID=8YFLogxK
U2 - 10.1093/cid/cir802
DO - 10.1093/cid/cir802
M3 - Article
C2 - 22095568
AN - SCOPUS:84855877378
SN - 1058-4838
VL - 54
SP - 424
EP - 433
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 3
ER -